Patent details

301296 Product Name: Gentherapie die de humane coagulatiefactor IX variant R338L tot uitdrukking brengt

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301296
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP4032979
Status:
Application Pending
Application number:
301296
Procedural language:
Dutch
First Applicant Residence Country:
Netherlands (NL)

Marketing Authorization

Marketing Authorization Number:
EU/1/22/1715
Marketing Authorization Type:
EEA
Marketing Authorization Date:
23/02/2023
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
01/11/2024
First Marketing Authorization date:
23/02/2023
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
01/11/2024
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
01/11/2024
 
 

 

Name:
uniQure biopharma B.V.
Address:
Paasheuvelweg 25a, 1105 BP Amsterdam, Netherlands (NL)

Agent

1

Name:
ir. B.Ch. Ledeboer c.s
From:
09/01/2025
Address:
V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:

2

Name:
ir. H.A. Witmans c.s.
From:
01/11/2024
Address:
V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:
09/01/2025

Publication

Bulletin

Bulletin Heading:
SPC
Journal edition number:
45/24
Publication date:
06/11/2024
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
12/03/2025 Incoming Correspondence Paper Accompanying letter incoming document 1 PDF /4/3/6/5/5/0801055634/docs/301296_13_incomingcorrespondencepaper20250312035751236.pdf
12/03/2025 SPC Documents Marketing Authorization SPC 4 PDF /4/3/6/5/5/0801055634/docs/301296_14_supplprotectioncertificate20250312035751285.pdf
06/11/2024 Outgoing Correspondence Confirmation receipt request 2 PDF /4/3/6/5/5/0801055634/docs/301296_12_630034l174.pdf
01/11/2024 Application Form First filed application form 3 PDF /4/3/6/5/5/0801055634/docs/301296_0_applicationform20241101012557733.pdf
01/11/2024 SPC Documents Accompanying letter SPC 4 PDF /4/3/6/5/5/0801055634/docs/301296_1_supplprotectioncertificate20241101012557782.pdf
01/11/2024 SPC Documents Marketing Authorization SPC 4 PDF /4/3/6/5/5/0801055634/docs/301296_2_supplprotectioncertificate20241101012557789.pdf
01/11/2024 SPC Documents Summary of the characteristics of the product 24 PDF /4/3/6/5/5/0801055634/docs/301296_3_supplprotectioncertificate20241101012557798.pdf
01/11/2024 SPC Documents Annex SPC 17 PDF /4/3/6/5/5/0801055634/docs/301296_4_supplprotectioncertificate20241101012557846.pdf
01/11/2024 SPC Documents Annex SPC 5 PDF /4/3/6/5/5/0801055634/docs/301296_5_supplprotectioncertificate20241101012557809.pdf
01/11/2024 SPC Documents Annex SPC 2 PDF /4/3/6/5/5/0801055634/docs/301296_6_supplprotectioncertificate20241101012557855.pdf
01/11/2024 SPC Documents Annex SPC 1 PDF /4/3/6/5/5/0801055634/docs/301296_7_supplprotectioncertificate20241101012557862.pdf
01/11/2024 SPC Documents Marketing Authorization SPC 3 PDF /4/3/6/5/5/0801055634/docs/301296_8_supplprotectioncertificate20241101013330918.pdf
01/11/2024 SPC Documents Summary of the characteristics of the product 24 PDF /4/3/6/5/5/0801055634/docs/301296_9_supplprotectioncertificate20241101013330934.pdf
01/11/2024 SPC Documents Annex SPC 17 PDF /4/3/6/5/5/0801055634/docs/301296_10_supplprotectioncertificate20241101013330948.pdf
01/11/2024 SPC Documents Annex SPC 5 PDF /4/3/6/5/5/0801055634/docs/301296_11_supplprotectioncertificate20241101013330941.pdf